Eur Rev Med Pharmacol Sci 2021; 25 (1): 14-15
DOI: 10.26355/eurrev_202101_24338

Comment on “A meta-analysis of influence of MSMB promoter rs10993994 polymorphisms on prostate cancer risk”

Y.-Y. Feng, H.-Y. Pan, Y.-Y. Mi, L.-J. Zhu

Wuxi Medical College, Jiangnan University, Wuxi, China. jndxfyzlj@163.com

Free PDF Download

To cite this article

Y.-Y. Feng, H.-Y. Pan, Y.-Y. Mi, L.-J. Zhu
Comment on “A meta-analysis of influence of MSMB promoter rs10993994 polymorphisms on prostate cancer risk”

Eur Rev Med Pharmacol Sci
Year: 2021
Vol. 25 - N. 1
Pages: 14-15
DOI: 10.26355/eurrev_202101_24338

Keywords Related articles:

  1. A meta-analysis of influence of MSMB promoter rs10993994 polymorphisms on prostate cancer risk
  2. Rectal/urinary toxicity after hypofractionated vs. conventional radiotherapy in high risk prostate cancer: systematic review and meta analysis
  3. ERCC polymorphisms and risk of osteosarcoma: a meta-analysis
  4. Prostate specific antigen as a biomarker for breast cancer: a meta-analysis study
  5. Potential effects of IL-17A rs2275913 and IL-17F rs763780 polymorphisms on susceptibility to gastric cancer in Chinese population: a meta-analysis